Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 838

Sort by

Sort Order Select

Journal Articles

Emerging therapies for inv(16) AML

Sridevi Surapally, Daniel G. Tenen, John A. Pulikkan

Blood (2021) 137 (19): 2579–2584.

https://doi.org/10.1182/blood.2020009933

Published: 2021

Journal Articles

Taking aim at IDH in fitter patients with AML

Andrew H. Wei, Naval Daver

Blood (2021) 137 (13): 1706–1707.

https://doi.org/10.1182/blood.2020009361

Published: 2021

Journal Articles

Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)

Eunice S. Wang, MD, Elizabeth A. Griffiths, MD, Roland B. Walter, MD PhD MS, Martin S. Tallman, MD, Aaron D Goldberg, MD PhD, Boo Messahel, MD, Richard M. Stone, MD

Blood (2019) 134 (Supplement_1): 3829.

https://doi.org/10.1182/blood-2019-130536

Published: 2019

Journal Articles

Brentuximab Vedotin As Consolidation Therapy Post Hematopoietic Stem Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma: A Real World Analysis of the Colombian Experience

Blood (2019) 134 (Supplement_1): 5275.

https://doi.org/10.1182/blood-2019-129295

Published: 2019

Journal Articles

Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

Pallavi Mehta, MD DM, Neha Yadav, BDS , MBA, Mohan Bhaarat, Sumeet Prakash Mirgh, MBBS, MDDM, Vishvdeep Khushoo, MBBS, MDDM, Shinto Francis Thekuddan, MBBS, MDDM, Narendra Agrawal, MD DM, Rayaz Ahmed, MDDM, Dinesh Bhurani, MD DM, FRCPA

Blood (2019) 134 (Supplement_1): 5572.

https://doi.org/10.1182/blood-2019-131674

Published: 2019

Journal Articles

Comparison of Fixed Dose, Reduced-Intensity Conditioning with Busulfan and Fludarabine to Reduced PK-Guided Busulfan AUC Conditioning in Patients Undergoing Hematopoietic Stem Cell Transplant for AML/MDS

Brendan Rasor, PharmD, Tyler Dickerson, PharmD, Qiuhong Zhao, MS, Jonathan E Brammer, MD, Karilyn Larkin, MD, Samantha Jaglowski, MDMPH, Alice S. Mims, MD, Sam Penza, MD, Sumithira Vasu, MDMBBS, Sarah A Wall, MD, Basem M. William, MRCP,MD, Ayman Saad, MD, Julianna Roddy, PharmD, Hannah K. Choe, MD, Marcin Puto, PharmD

Blood (2019) 134 (Supplement_1): 5715.

https://doi.org/10.1182/blood-2019-123657

Published: 2019

Journal Articles

Relapsed Follicular Lymphoma and Haploidentical Transplantation Using Double Source of Hematopoietic Stem Cells and Post-Transplant Cyclophosphamide: Case Report

Ana Rojas Fonseca, Nelson Hamerschlak, MD PhD, José Salvador Rodrigues de Oliveira, MD PhD

Blood (2019) 134 (Supplement_1): 5718.

https://doi.org/10.1182/blood-2019-125208

Published: 2019

Journal Articles

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Takashi Kumagai, MD PhD, Chiaki Nakaseko, MD PhD, Kaichi Nishiwaki, MD, Chikashi Yoshida, MD PhD, Kazuteru Ohashi, MD PhD, Naoki Takezako, MD PhD, Hina Takano, MD PhD, Yasuji Kouzai, MD PhD, Tadashi Murase, MD PhD, Kosei Matsue, MD PhD, Satoshi Morita, PhD Prof., Junichi Sakamoto,, MD PhD, Hisashi Wakita, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof.

Blood (2019) 134 (Supplement_1): 4154.

https://doi.org/10.1182/blood-2019-130504

Published: 2019

Journal Articles

Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia

Fermin Sanchez-Guijo, MD PhD, Sergio Matarraz, Eleni Plata, Miguel Sagüés, Montserrat Cortes, Irena Preloznik Zupan, Monica Crugnola, MD, Giovanni Caocci, MD, Heather Oakervee, BSc, MBBS, MD MRCP, FRCPath, Tobias Gedde-Dahl, Krzysztof Warzocha, Wieslaw W. Jedrzejczak, Slawomira Kyrcz-Krzemien, MD PhD, Alexander Kiani, Sharon Supekar, AnaRita Ferreira, Seema Shah, Juan Luis Steegmann, Michele Baccarani, MD

Blood (2019) 134 (Supplement_1): 4160.

https://doi.org/10.1182/blood-2019-124710

Published: 2019

Journal Articles

Value of Flow Cytometry for MRD-Based Relapse Prediction in B-Cell Precursor Acute Lymphoblastic Leukemia in a Multi-Center Setting

Blood (2019) 134 (Supplement_1): 2755.

https://doi.org/10.1182/blood-2019-122311

Published: 2019

Journal Articles

Pilot Study on the Safety of Intravenous Arsenic Trioxide and Oral Realgar-Indigo Naturalis Formula Administrated in Children with Acute Promyelocytic Leukemia: A Single-Center Study

Linya Wang, MD, Yuanyuan Zhang, MD, Ruidong Zhang, MD PhD, Jiaole Yu, PhD MD, Ying Wu, MD, Wei Lin, Peijing Qi, Jia Fan, Jing Li, PhD, Jiayan Lin, Xueling Zheng, Hairu Hu, Xiaoxia Peng, Hui Jiang, PhD, Huyong Zheng, MD PhD

Blood (2019) 134 (Supplement_1): 2611.

https://doi.org/10.1182/blood-2019-128196

Published: 2019

Journal Articles

Multicentre, Open Label, Randomized Phase III Study of Cpi-613 ® (devimistat) in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥ 60 years) with Relapsed / Refractory Acute Myeloid Leukemia (AML) - Armada 2000 (AML003) Trial

Timothy S. Pardee, MD PhD, Sanjeev Luther, MBA, Marc E. Buyse, ScD, Bayard L Powell, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 2658.

https://doi.org/10.1182/blood-2019-129377

Published: 2019

Journal Articles

Baseline Total Lesion Glycolysis Combined with Interim PET/CT Is a Robust Predictor of Outcome in Patients with Peripheral T-Cell Lymphoma

Akihiro Kitadate, MD PhD, Kentaro Narita, MD, Kota Fukumoto, MD, Toshiki Terao, MD, Takafumi Tsushima, MD, Hiroki Kobayashi, MD, Yoshiaki Abe, MD, Daisuke Miura, MD, Masami Takeuchi, MD, Youichi Machida, MD, Naoto Takahashi, MD PhD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 2839.

https://doi.org/10.1182/blood-2019-122799

Published: 2019

Journal Articles

Efficacy and Safety of Daily All-Trans Retinoic Acid Monotherapy As Maintenance Therapy for Acute Promyelocytic Leukemia

Yoo Jin Lee, MD PhD, Seo-Yeon Ahn, MD, Jae-Cheol Jo, MD PhD, Yunsuk Choi, MD, Ji Hyun Lee, MD PhD

Blood (2019) 134 (Supplement_1): 3898.

https://doi.org/10.1182/blood-2019-125671

Published: 2019

Journal Articles

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

C. Michel Zwaan, MD PhD, Edward Anders Kolb, MD, Derek E. Mires, PharmD, Michele Vigliotti, PharmD, Jingdong Xie, PhD, Pamela Downs, BS, Arthur P DeCillis, MD MS, Cara A Rabik, MD PhD, Todd M Cooper, DO

Blood (2019) 134 (Supplement_1): 3937.

https://doi.org/10.1182/blood-2019-121736

Published: 2019

Journal Articles

Evaluating the Utilization of All- T rans Retinoic Acid and Arsenic Trioxide during Consolidation Therapy for Patients Receiving Treatment for Acute Promyelocytic Leukemia

Laura A Bowers, PharmD, Maho Hibino, PharmD, Rebecca Garcia Hunt, PharmD, Leslie Renee Ellis, MD, Rupali Bhave, MD, Dianna S. Howard, MD, Susan Lyerly, P.A.-C., Sarah Dralle, NP, Megan Manuel, NP, Timothy S. Pardee, MD PhD, Bayard L Powell, MD

Blood (2019) 134 (Supplement_1): 3901.

https://doi.org/10.1182/blood-2019-131817

Published: 2019

Journal Articles

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Dirk Reinhardt, MD, Christian Michel Zwaan, Albert Hoenekopp, Julie Niolat, Sophie Ifrah, Florence Noel-Baron, Franco Locatelli, MD

Blood (2019) 134 (Supplement_1): 3835.

https://doi.org/10.1182/blood-2019-128043

Published: 2019

Journal Articles

Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML)

Richard M. Stone, MD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Caroline Kokulis, Jeremy M. Stewart, BA, Michael McGinnis, Lillian Werner, MS, Anthony G. Letai, MD PhD, Marina Y Konopleva, MD PhD, Marlise Luskin, MDMS

Blood (2019) 134 (Supplement_1): 3908.

https://doi.org/10.1182/blood-2019-124966

Published: 2019

Journal Articles

The Efficacy and Safety of Cladribine in Combination with Cytarabine ,ATRA, G-CSF and Mitoxantrone(Claag-M Regimen)in Relapsed/Refractory AML : A Phase 1/2, Prospective, Single-Arm, Multicenter Study

Tinghua Zhang, Yinghua Xie, Limin Zhao, Xiyao Han, Yingting Lu, Jing Zhang, Yanhui Xie, Qi Zhu, Lihua Sun, Li Yang, Ligen Liu

Blood (2019) 134 (Supplement_1): 3843.

https://doi.org/10.1182/blood-2019-125739

Published: 2019

Journal Articles

Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols

Serena Rosati, MD, Massimo Breccia, MD, Carmelo Gurnari, MD, Ida Carmosino, Emilia Scalzulli, MD, Enrico Montefusco, Salvatore Perrone, MD, Ombretta Annibali, Vincenza Martini, MD, Giulio Trapè, Malgorzata Monika Trawinska, MD, Clara Minotti, MD, Giuseppe Cimino, MD, Agostino Tafuri, MD, Giuseppe Avvisati, MD, Maria Teresa Voso, MD, Robin Foà, MD, Roberto Latagliata

Blood (2019) 134 (Supplement_1): 3845.

https://doi.org/10.1182/blood-2019-129216

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Emerging therapies for inv(16) AML

Taking aim at IDH in fitter patients with AML

Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)

Brentuximab Vedotin As Consolidation Therapy Post Hematopoietic Stem Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma: A Real World Analysis of the Colombian Experience

Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

Comparison of Fixed Dose, Reduced-Intensity Conditioning with Busulfan and Fludarabine to Reduced PK-Guided Busulfan AUC Conditioning in Patients Undergoing Hematopoietic Stem Cell Transplant for AML/MDS

Relapsed Follicular Lymphoma and Haploidentical Transplantation Using Double Source of Hematopoietic Stem Cells and Post-Transplant Cyclophosphamide: Case Report

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia

Value of Flow Cytometry for MRD-Based Relapse Prediction in B-Cell Precursor Acute Lymphoblastic Leukemia in a Multi-Center Setting

Pilot Study on the Safety of Intravenous Arsenic Trioxide and Oral Realgar-Indigo Naturalis Formula Administrated in Children with Acute Promyelocytic Leukemia: A Single-Center Study

Baseline Total Lesion Glycolysis Combined with Interim PET/CT Is a Robust Predictor of Outcome in Patients with Peripheral T-Cell Lymphoma

Efficacy and Safety of Daily All-Trans Retinoic Acid Monotherapy As Maintenance Therapy for Acute Promyelocytic Leukemia

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Evaluating the Utilization of All- T rans Retinoic Acid and Arsenic Trioxide during Consolidation Therapy for Patients Receiving Treatment for Acute Promyelocytic Leukemia

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML)

The Efficacy and Safety of Cladribine in Combination with Cytarabine ,ATRA, G-CSF and Mitoxantrone(Claag-M Regimen)in Relapsed/Refractory AML : A Phase 1/2, Prospective, Single-Arm, Multicenter Study

Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only